Joaquina Baranda, MD
Medical Oncology · Westwood, KSNPI 1801989041
Payments from drug & device makers
Across 356 payments — averaging $7532.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.1M
- Exelixis Inc.$647K
- Astellas Pharma Global Development$381K
- Pfizer$229K
- AstraZeneca$110K
- Incyte Corporation$107K
- plus $127K from 9 others
Across 12 payments — averaging $778.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$8K
- Regeneron$868
- Pharmacyclics LLC, An Abbvie Company$110
What the payments were for
- Speaking & faculty fees$3,70021%
- Travel & lodging$13,10974%
- Food & beverage$8315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 86 | $1,080,561 |
| Exelixis Inc. | 95 | $647,071 |
| Astellas Pharma Global Development | 82 | $381,229 |
| Pfizer | 41 | $229,274 |
| AstraZeneca | 1 | $109,924 |
| Incyte Corporation | 11 | $106,828 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $46,675 |
| Amgen | 1 | $29,715 |
| Eli Lilly | 2 | $21,467 |
| Regeneron | 11 | $14,072 |
| Sanofi-aventis U.S. LLC | 8 | $13,466 |
| Merck | 2 | $814 |
| Genentech, Inc. | 2 | $238 |
| Johnson & Johnson | 1 | $119 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$13,386
- Erleada$119
How this compares
$2,681,474 in reported general payments places this provider in the 80th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Westwood
- Weijing SunWestwood$5.1M
- Rahul ParikhWestwood$4.5M
- Anwaar SaeedWestwood$4.1M
- Anne OdeaWestwood$2.2M
- Stephen WilliamsonWestwood$861K
- Elizabeth WulffWestwood$529K
- Saqib AbbasiWestwood$108K
- Sarah TaylorWestwood$56K
- Ajjai AlvaOverland Park$3.7M
- Nisreen HaideriOverland Park$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.